Quarterly report · Q1
4543.TEDINET S100RML8
Period2023-04-01 → 2023-06-30
Filed2023-08-10
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥215.3bn | 2023-04-01 → 2023-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥820.2bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥197.3bn | 2022-04-01 → 2022-06-30 | Cons. | Revenue IFRS |
| Operating income | ¥29.6bn | 2023-04-01 → 2023-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥30.4bn | 2022-04-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥29.8bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥116.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥29.7bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥22.5bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥89.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥22.4bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥22.5bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥22.4bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥1.67T | at 2023-06-30 | Cons. | Assets IFRS |
| Total assets | ¥1.60T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.58T | at 2022-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥468.1bn | at 2023-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥491.2bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.20T | at 2023-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.11T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.12T | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.01T | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.20T | at 2023-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.11T | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.12T | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥160.1bn | at 2023-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥187.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥209.6bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.3bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥11.4bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥117.5bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥23.4bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥19.3bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥59.1bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥16.1bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥27.5bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥86.6bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥14.8bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥30.28 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥119 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥29.61 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥30.27 | 2023-04-01 → 2023-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥118.95 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥29.6 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 72.0% | at 2023-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 69.3% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 70.5% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2023-06-30 | ¥62m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | −¥1.1bn |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥40.9bn |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥5.9bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥130.6bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥26.9bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥43.7bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥2.8bn |
| —segment total | revenue external | 2023-04-01 → 2023-06-30 | ¥215.2bn |
| —segment total | segment profit | 2023-04-01 → 2023-06-30 | ¥35.6bn |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-06-30 | ¥62m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥198m |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥34.5bn |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥3.6bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥116.8bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥28.0bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥46.0bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥4.5bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥197.3bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥36.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 561
| Item | Context | Value | Unit |
|---|---|---|---|
| Equity IFRS | CurrentQuarterInstant_OtherComponentsOfEquityIFRSMember | 242412000000 | JPY |
| Equity IFRS | CurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember | 1202660000000 | JPY |
| Equity IFRS | CurrentQuarterInstant | 1202660000000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | 29667000000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | 29804000000 | JPY |
| Depreciation and amortization ope cf IFRS | Prior1YTDDuration | 16612000000 | JPY |
| Depreciation and amortization ope cf IFRS | CurrentYTDDuration | 17959000000 | JPY |
| Impairment losses reversal of impairment losses ope cf IFRS | Prior1YTDDuration | 1699000000 | JPY |
| Impairment losses reversal of impairment losses ope cf IFRS | CurrentYTDDuration | － | JPY |
| Share of loss profit of investments accounted for using equity method ope cf IFRS | Prior1YTDDuration | 10000000 | JPY |
| Share of loss profit of investments accounted for using equity method ope cf IFRS | CurrentYTDDuration | -11000000 | JPY |
| Increase or decrease in retirement benefit asset or liability ope cf IFRS | Prior1YTDDuration | 811000000 | JPY |
| Increase or decrease in retirement benefit asset or liability ope cf IFRS | CurrentYTDDuration | 689000000 | JPY |
| Interest and dividend income ope cf IFRS | Prior1YTDDuration | -259000000 | JPY |
| Interest and dividend income ope cf IFRS | CurrentYTDDuration | -438000000 | JPY |
| Interest expenses ope cf IFRS | Prior1YTDDuration | 767000000 | JPY |
| Interest expenses ope cf IFRS | CurrentYTDDuration | 409000000 | JPY |
| Foreign exchange loss gain ope cf IFRS | Prior1YTDDuration | 2313000000 | JPY |
| Foreign exchange loss gain ope cf IFRS | CurrentYTDDuration | -553000000 | JPY |
| Loss gain on sale and retirement of fixed assets ope cf IFRS | Prior1YTDDuration | -17000000 | JPY |
| Loss gain on sale and retirement of fixed assets ope cf IFRS | CurrentYTDDuration | -324000000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | Prior1YTDDuration | 1305000000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | CurrentYTDDuration | 1315000000 | JPY |
| Decrease increase in inventories ope cf IFRS | Prior1YTDDuration | -4545000000 | JPY |
| Decrease increase in inventories ope cf IFRS | CurrentYTDDuration | -5161000000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | Prior1YTDDuration | -4050000000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | CurrentYTDDuration | -6358000000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1YTDDuration | -11262000000 | JPY |
| Other changes in working capital ope cf IFRS | CurrentYTDDuration | -9018000000 | JPY |
| Subtotal ope cf IFRS | Prior1YTDDuration | 33052000000 | JPY |
| Subtotal ope cf IFRS | CurrentYTDDuration | 28312000000 | JPY |
| Interest and dividends received ope cf IFRS | Prior1YTDDuration | 792000000 | JPY |
| Interest and dividends received ope cf IFRS | CurrentYTDDuration | 1154000000 | JPY |
| Interest paid ope cf IFRS | Prior1YTDDuration | -543000000 | JPY |
| Interest paid ope cf IFRS | CurrentYTDDuration | -470000000 | JPY |
| Income taxes refund paid ope cf IFRS | Prior1YTDDuration | -9940000000 | JPY |
| Income taxes refund paid ope cf IFRS | CurrentYTDDuration | -17565000000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YTDDuration | 23361000000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYTDDuration | 11431000000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | Prior1YTDDuration | -11523000000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | CurrentYTDDuration | -14651000000 | JPY |
| Proceeds from sale of property plant and equipment inv cf IFRS | Prior1YTDDuration | 48000000 | JPY |
| Proceeds from sale of property plant and equipment inv cf IFRS | CurrentYTDDuration | 611000000 | JPY |
| Purchase of intangible assets inv cf IFRS | Prior1YTDDuration | -4195000000 | JPY |
| Purchase of intangible assets inv cf IFRS | CurrentYTDDuration | -4463000000 | JPY |
| Purchase of marketable securities inv cf IFRS | Prior1YTDDuration | -394000000 | JPY |
| Purchase of marketable securities inv cf IFRS | CurrentYTDDuration | -691000000 | JPY |
| Proceeds from sale of marketable securities inv cf IFRS | Prior1YTDDuration | 78000000 | JPY |
| Proceeds from sale of marketable securities inv cf IFRS | CurrentYTDDuration | － | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | Prior1YTDDuration | -135000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |